As we close out the first half of 2018, I’d like to take a moment to reflect on Agendia’s recent achievements as a
global leader in precision oncology and provide an update on forward-looking expansions that will have a positive
impact on patients and their doctors.

Our mission is to provide best in class precision oncology tools, and we have seen year-over-year double-digit growth
as more women than ever before are able to access the benefits of our MammaPrint and BluePrint tests – and this is
just the beginning.

We achieved a major milestone last month when we
announced a $35 million investment from Athyrium Capital Management. This financial partnership will help
expand Agendia’s commercial footprint in the U.S. and internationally. It will also further the adoption of our next-generation
sequencing-based MammaPrint BluePrint Kit and will facilitate investment in our Big Data programs that will
help identify new biomarkers for breast cancer.

Our science continues to stand apart from the competition. Recent
clinical data underscored the value of the landmark MINDACT trial and highlighted the role of MammaPrint in
providing clear answers about the benefits of chemotherapy treatment for women of all ages. We were recognized in
major international clinical practice guidelines for breast cancer treatment, and to this day, MammaPrint remains
the only genomic test recommended for women with lymph node-positive disease by the
American Society of Clinical Oncology (ASCO).

These recommendations, based on the results from the MINDACT trial, led to positive
coverage decisions by major healthcare insurers in the U.S.  We also identified opportunities for expanded
adoption of our MammaPrint and BluePrint tests by hospitals and diagnostic labs around the world including most
recently in France
and
Southeast Asia.

On the horizon, we anticipate exciting clinical developments from the FLEX, PRECiSE, I-SPY2 and MINDACT trials in the
next year. We also plan to expand Agendia’s precision oncology pipeline through new collaborative research programs
with leading academic institutions.

At Agendia, we believe it is the collective responsibility of the entire cancer care community to deliver precision
oncology so we can minimize suffering and enable cancer patients to live the longest and healthiest lives possible.
Our strength is in our data, our partnerships, and our commitment to our patients. I’m confident in our achievements
as a company and look forward to what the future holds.

Mark R. Straley
Chief Executive Officer, Agendia